The effect of thymosin treatment of venous ulcers

Annals of the New York Academy of Sciences

Volumn 1194, Issue , 2010, Pages 207-212

  Guarnera, G ^a   Derosa, A ^b   Camerini, R ^b  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b Sigma Tau SpA   (Italy)

Author keywords

CEAP classification; Pain and quality of life; Thymosin beta 4; Venous ulcers; Wound healing

Indexed keywords

PLACEBO; THYMOSIN;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; ULCER; ULCER HEALING; UNSPECIFIED SIDE EFFECT; VENOUS STASIS;

EID: 77951832222     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05490.x     Document Type: Conference Paper

References (20)

1. Bergqvist, D., C. Lindholm & O. Nelzen. 1999. Chronic leg ulcers: the impact of venous disease. J. Vasc. Surg. 29: 752-755.
2. Nelzen,O. 2000. Leg ulcers: economic aspects.Phlebology 15: 110-114.
3. Philips, T.J. 1994. Chronic cutaneous ulcers: etiology and epidemiology. J. Invest. Dermatol. 102: 38S- 41S.
4. Ryan, S., C. Eager & R.G. Sibbald. 2003. Venous leg ulcer pain. Ostomy Wound Manage 49(4 Suppl.): 16-23.
5. Mayer,W.,W. Jochmann&H. Partsch. 1994.Varicose ulcer: healing in conservative therapy: a prospective study. Wien. Med. Wochenschr. 144: 250-252.
6. Browse, N.L. & K.G. Bernard. 1982. The cause of venous ulceration. Lancet 2: 243-245.
7. Coleridge, Smith, P.D., P. Thomas, J.H. Scurr, et al. 1988. Causes of venous ulceration: a new hypothesis. Br. Med. J. 296: 1726-1727.
8. Falanga, V. & W.H. Eaglstein. 1993. The "trap" hypothesis of venous ulceration. Lancet 341: 1006-1008.
9. Margolis, D.J. & J.H. Cohen. 1994. Management of chronic venous leg ulcers: a literature-guided approach. Clin. Dermatol. 12: 19-26.
10. Skene, A.J., J.M. Smith, C.J. Dore, et al. 1992. Venous leg ulcers: a prognostic index to predict time to healing. BMJ 305: 1119-1121.
11. Margolis,D.J., J.A. Berlin&B.L. Strom. 1999. Risk factors associated with the failure of a venous leg ulcer to heal. Arch. Dermatol. 135: 920-926.
12. Gohel, M.S., M. Taylor, J.J. Earnshaw, et al. 2005. Risk factors for delayed healing and recurrence of chronic venous leg ulcers-analysis of 1324 legs. Eur. J. Vasc. Endovasc. Surg. 29: 74-77.
13. Zamboni, P., S. Tognazzo, M. Izzo, et al. 2005.Hemocromatosis C282Y gene mutation increases the risk of venous leg ulceration. J. Vasc. Surg. 42: 309-314.
14. Huff, T., C.S. Muller, A.M. Otto, et al. 2001. Beta- Thymosin, small acidic peptideswithmultiple functions. Int. J. Biochem. Cell Biol. 33: 205-220.
15. Malinda, K.M., G.S. Sidhu, H. Mani, et al. 1999. Thymosin beta 4 accelerates wound healing. J. Invest. Dermatol. 113: 364-368.
16. Goldstein, A.L., E. Hannapel & H.K. Kleinman. 2005. Thymosin Beta 4: actin-sequestering proteinmoonlights to repair injured tissues. Trends Mol. Med. 11: 421-429.
17. RegeneRx Biopharmaceuticals, Inc., Bethesda, Maryland. A Phase I Double-Blind, Placebo-Controlled Dose Escalation Study of the Safety and Tolerability of Topically Administered Thymosin Beta 4 in Normal Healthy Volunteers. Final clinical study report dated March 10, 2004
18. US Department of Health and Human Services, Food and Drug Administration. Guidance for industry: chronic cutaneous ulcer and burn wounds - developing products for treatment. Draft Guidance dated June 2000.
19. Beebe, H.G., J.J. Bergan, D. Bergqvist, et al. 1995. Classification and grading of chronic venous disease in the lower limbs. A consensus statement. Phlebology 10: 42-45.
20. Guarnera, G., G. Tinelli, D. Abeni, et al. 2007. Pain and quality of life in patients with vascular leg ulcers: an Italian multicentre study. J. Wound Care 16: 347-351.